Zinc Carnosine Metal–Organic Coordination Polymer as a Potent Broadly Active Influenza Vaccine Platform with In Vitro Shelf-Stability

• Published in: Molecular pharmaceutics Vol. 20; no. 9; pp. 4687 - 4697
• Main Authors: Hendy, Dylan A., Lifshits, Liubov M., Batty, Cole J., Carlock, Michael A., Ross, Ted M., Mousa, Jarrod J., Bachelder, Eric M., Ainslie, Kristy M.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 04.09.2023
• Subjects: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Animals; Carnosine; Humans; Influenza Vaccines; Influenza, Human; Mice; Polymers; influenza; broadly active antigen; storage stability; vaccine; coordination polymer
• ISSN: 1543-8384; 1543-8392
• DOI: 10.1021/acs.molpharmaceut.3c00424

Current seasonal influenza vaccines are limited in that they need to be reformulated every year in order to account for the constant mutation of the virus. Hemagglutinin (HA) immunogens have been developed using a computationally optimized broadly reactive antigen (COBRA) methodology, which are able to elicit an antibody response that neutralizes antigenically distinct influenza strains; however, subunit proteins are not immunogenic enough on their own to generate a substantial immune response. Due to this, different delivery strategies and adjuvants can be used to improve immunogenicity. Recently, we reported a new coordination polymer composed of the dipeptide carnosine and zinc (ZnCar) that is able to deliver protein antigens along with CpG to generate a potent immune response. In the present work, ZnCar was used to deliver the COBRA HA immunogen Y2 and the adjuvant CpG. We incorporated Y2 into ZnCar using two different methods to assess which would be the most immunogenic. Mice vaccinated with Y2 and CpG complexed with ZnCar showed an improved humoral and cellular response when compared to mice vaccinated with soluble Y2 and CpG. Further, we demonstrate in vitro that when Y2 and CpG are coordinated with ZnCar, they are protected from degradation at 40 °C for 3 months or 24 °C for 6 months. Overall, ZnCar shows promise as a delivery vehicle for subunit vaccines, given its superior immunogenicity and in vitro storage stability.